- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Premier issues nuclear group buy
ADAC Laboratories of Milpitas, CA, and Siemens Medical Systems of Hoffman Estates, IL, have been named the preferred vendors in a dual-source group buy of nuclear medicine equipment issued by group purchasing organization Premier. Premier members are
ADAC Laboratories of Milpitas, CA, and Siemens Medical Systems of Hoffman Estates, IL, have been named the preferred vendors in a dual-source group buy of nuclear medicine equipment issued by group purchasing organization Premier. Premier members are expected to purchase at least $20 million in equipment from the two companies, according to Pam Parker, director of group buys at the San Diego-based GPO.
Premier selected ADAC and Siemens after surveys of Premier members indicated that the two companies were the highest favored gamma camera vendors, Parker said. Premier members have until mid-May to issue purchase orders that will allow them to lock in the pricing discounts reached under agreement with ADAC and Siemens. Some 62 Premier hospitals have indicated that they are interested in participating in the group buy.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
